Shanghai Haohai Biological Technology (DB:5HB) - Hisse Senedi Fiyatı, Haberler ve Analizler

5HB Stoklara Genel Bakış

Shanghai Haohai Biological Technology Co, Ltd. Daha fazla detay

5HB temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	5/6
Finansal Sağlık	5/6
Temettüler	3/6

Ödüller

Adil değer tahminimizden 79% daha düşük bir oranda işlem görüyor

Kazançların yılda 16.82% oranında artması öngörülüyor

Kazançlar geçen yıl 24.5% oranında arttı

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Son 3 ayda dalgalı hisse senedi fiyatı

Kararsız temettü geçmişi

Shanghai Haohai Biological Technology Co., Ltd. Rakipler

Biotest

XTRA:BIO3

€1.3b

Formycon

XTRA:FYB

€882.8m

2invest

XTRA:2INV

€64.4m

Dermapharm Holding

XTRA:DMP

€2.0b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Shanghai Haohai Biological Technology
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$3.30
52 Haftanın En Yüksek Seviyesi	HK$4.70
52 Haftanın En Düşük Seviyesi	HK$2.60
Beta	0.76
11 Aylık Değişim	-4.07%
3 Aylık Değişim	-7.82%
1 Yıllık Değişim	-4.94%
33 Yıllık Değişim	-18.23%
5 Yıllık Değişim	-7.60%
Halka arzdan bu yana değişim	-25.66%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	5HB	DE Biotechs	DE Pazar
7D	-2.4%	1.1%	1.3%
1Y	-4.9%	-18.5%	7.9%

Getiri vs. Endüstri: 5HB geçen yıl % -18.5 oranında getiri sağlayan German Biotechs sektörünü aştı.

Getiri vs Piyasa: 5HB geçen yıl % 7.9 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 5HB's price volatile compared to industry and market?
5HB volatility
5HB Average Weekly Movement	8.0%
Biotechs Industry Average Movement	6.7%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 5HB hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 5HB 'nin haftalık oynaklığı ( 8% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2007	2,179	Jianying Wu	www.3healthcare.com

Shanghai Haohai Biological Technology Co, Ltd. Çin, Avrupa, Amerika Birleşik Devletleri ve uluslararası alanda biyomedikal malzemelerin araştırılması, geliştirilmesi, üretimi ve satışı ile uğraşmaktadır. Şirket, göz içi lens, tıbbi sodyum hyaluronat jel ve kayganlaştırıcı göz damlasından oluşan oftalmoloji ürünleri sunmaktadır.

Shanghai Haohai Biological Technology Co., Ltd. Temel Bilgiler Özeti

Shanghai Haohai Biological Technology'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
5HB temel i̇stati̇sti̇kler
Piyasa değeri	€1.70b
Kazançlar(TTM)	€56.27m
Gelir(TTM)	€359.28m

13.8x

F/K Oranı

2.2x

P/S Oranı

5HB aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
5HB gelir tablosu (TTM)
Gelir	CN¥2.75b
Gelir Maliyeti	CN¥848.86m
Brüt Kâr	CN¥1.90b
Diğer Giderler	CN¥1.47b
Kazançlar	CN¥430.21m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	1.87
Brüt Marj	69.10%
Net Kâr Marjı	15.66%
Borç/Özkaynak Oranı	7.0%

5HB uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

3.1%

Mevcut Temettü Verimi

85%

Ödeme Oranı

5HB Stoklara Genel Bakış

Ödüller

Risk Analizi

Shanghai Haohai Biological Technology Co., Ltd. Rakipler

XTRA:BIO3

€1.3b

XTRA:FYB

€882.8m

XTRA:2INV

€64.4m

XTRA:DMP

€2.0b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Third quarter 2024 earnings released: EPS: CN¥2.19 (vs CN¥0.36 in 3Q 2023)

Investor sentiment improves as stock rises 21%

Shanghai Haohai Biological Technology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Shanghai Haohai Biological Technology Co., Ltd. Approves Interim Dividend for the Six Months Ended 30 June 2024

Upcoming dividend of CN¥0.40 per share

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) announces an Equity Buyback for 2,229,405 shares, representing 0.95% for CNY 200 million.

Recent updates

Third quarter 2024 earnings released: EPS: CN¥2.19 (vs CN¥0.36 in 3Q 2023)

Investor sentiment improves as stock rises 21%

Shanghai Haohai Biological Technology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Shanghai Haohai Biological Technology Co., Ltd. Approves Interim Dividend for the Six Months Ended 30 June 2024

Upcoming dividend of CN¥0.40 per share

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) announces an Equity Buyback for 2,229,405 shares, representing 0.95% for CNY 200 million.

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2024 Results on Aug 17, 2024

New major risk - Revenue and earnings growth

Shanghai Haohai Biological Technology Co., Ltd. Announces to Distribute A Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of CN¥1.00 per share

First quarter 2024 earnings released: EPS: CN¥0.58 (vs CN¥0.47 in 1Q 2023)

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, May 29, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: CN¥2.44 (vs CN¥1.04 in FY 2022)

Shanghai Haohai Biological Technology Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Now 21% overvalued

Investor sentiment deteriorates as stock falls 16%

Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2023

Shanghai Haohai Biological Technology Co., Ltd. Announces Resignation of Guo Yongqing as Independent Non-Executive Director, Chairman of Audit Committee, Member of Remuneration and Appraisal Committee and Member of Nomination Committee

Third quarter 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.32 in 3Q 2022)

Investor sentiment deteriorates as stock falls 15%

Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Financial Guidance for the Nine Months Ended 30 September 2023

Investor sentiment improves as stock rises 17%

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) announces an Equity Buyback.

Second quarter 2023 earnings released: EPS: CN¥0.73 (vs CN¥0.059 in 2Q 2022)

Shanghai Haohai Biological Technology Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Upcoming dividend of HK$0.44 per share at 1.4% yield

Shanghai Haohai Biological Technology Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2022, Payable on August 11, 2023

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 12, 2023

First quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.35 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥1.04 (vs CN¥2.00 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Shanghai Haohai Biological Technology Co., Ltd. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: CN¥0.059 (vs CN¥0.76 in 2Q 2021)

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2022 Results on Aug 26, 2022

Shanghai Haohai Biological Technology Co., Ltd. Provides Financial Guidance for the Six Months Ended 30 June 2022

Upcoming dividend of HK$0.82 per share

Shanghai Haohai Biological Technology Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2021

Investor sentiment improved over the past week

Shanghai Haohai Biological Technology Co., Ltd. Announces Retirement of Li Yingqi as Independent Non-Executive Director

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 29, 2022

Full year 2021 earnings released: EPS: CN¥2.00 (vs CN¥1.30 in FY 2020)

Less than half of directors are independent

Shanghai Haohai Biological Technology Co., Ltd. to Report Q1, 2022 Results on Apr 29, 2022

Shanghai Haohai Biological Technology Co., Ltd. Proposes Ordinary Final Dividend for the Year Ended December 31, 2021

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues miss analyst expectations

Shanghai Haohai Biological Technology Co., Ltd. Provides Group Earnings Guidance for the Year Ended 31 December 2021

Third quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.50 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.76 (vs CN¥0.29 in 2Q 2020)

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.61 per share

Investor sentiment improved over the past week

Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ending June 30, 2021